ArchiveOctober 2010

Improvement in MS disability after Alemtuzumab

Treatment of early RRMS with Alemtuzumab reduces relapses and the accumulation of disability compared to interferon β. Remarkably PwMS treated with alemtuzumab experienced an improvement in disability at 6 months that was sustained for at least 3 years in comparison to those treated with interferon β. Critics have poopooed this observation as the study was single-blinded and liable to unblinding;...

Translate

Categories

Recent Posts

Recent Comments

Archives